PTC Therapeutics Says FDA Lifts Clinical Hold On Investigational Study In Patients With Rare Weak Nerve Cell Disorder

PTC Therapeutics released interim results from its Phase 2 PIVOT-HD study on PTC518 for Huntington's disease. The FDA has lifted the partial clinical hold on the program. read more

Continue reading at Benzinga ยป

Biotech, Briefs, Equities, News, PTCT, Stories That Matter, Health Care, FDA, General, PTCT, News, Biotech, Equities, Health Care, FDA, General, Benzinga